Faeth Therapeutics Price Target Cut to $69.00/Share From $70.00 by Guggenheim

What happened

Guggenheim cut its price target for Faeth Therapeutics to $69.00 per share from $70.00, while maintaining its Buy rating, according to the supplied article. The article identifies this as an analyst ratings action.

Confirmed

Global impact / market context

The lower target indicates Guggenheim sees less potential value per share than before, but keeping the Buy rating signals it still views the shares positively. A target change is an analyst estimate, not a change to the company’s revenue, costs, or cash available.

Analyst inference

The supplied report gives no reason for the target cut and provides no operating or financial details about Faeth Therapeutics. Investors therefore cannot tell from this item whether the change reflects company prospects, valuation assumptions, or another consideration.

Confirmed

What to watch

1. Watch for another Guggenheim rating action on Faeth Therapeutics; the supplied report gives no reason for the one-dollar target reduction or explains its valuation assumptions. Analyst inference
2. Check whether Faeth Therapeutics later comments on the target change, since the report provides no company response or information about effects on sales, costs, or funding. Analyst inference
3. The report records Guggenheim maintaining its Buy rating while lowering the target to $69.00 per share from $70.00; it gives no further analyst rationale. Confirmed

Evidence

• Original source link unavailable